Sunesis pharmaceuticals inc. (SNSS)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenue:
License and other revenue

0

-

-

-

-

237

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

License and other revenue

-

-

-

-

-

-

-

-

-

-

-

1,955

2,565

2,536

2,530

2,603

2,847

3,061

3,287

3,458

4,593

5,734

6,827

7,962

7,962

7,956

6,232

5,743

0

-

0

0

-

5,000

5,000

4,000

0

0

0

Total revenues

-

-

-

-

-

-

-

-

-

-

-

1,955

2,565

2,536

2,530

2,603

2,847

3,061

3,287

3,458

4,593

5,734

6,827

7,962

7,962

7,956

6,232

5,743

0

-

0

0

-

5,000

5,000

4,014

0

0

0

Operating expenses:
Research and development

15,854

15,412

13,766

13,819

13,894

14,615

14,988

18,164

19,347

21,540

22,681

21,169

22,834

22,881

25,694

25,702

25,398

23,701

22,041

23,721

24,625

27,665

28,580

28,598

29,066

28,891

29,597

29,518

29,916

29,185

27,922

27,261

25,139

22,563

19,716

16,469

0

0

0

General and administrative

9,738

9,949

9,928

10,111

10,412

11,332

11,633

12,118

12,965

13,548

14,722

15,436

15,762

16,115

16,563

16,668

17,846

18,662

20,362

23,594

24,806

23,112

19,728

15,309

11,811

10,838

10,613

10,137

9,430

9,175

8,861

8,685

8,478

8,303

7,948

7,655

0

0

0

Total operating expenses

25,592

25,361

23,694

23,930

24,306

25,947

26,621

30,282

32,312

35,088

37,403

36,605

38,596

38,996

42,257

42,370

43,244

42,363

42,403

47,315

49,431

50,777

48,308

43,907

40,877

39,729

40,210

39,655

39,346

38,360

36,783

35,946

33,617

30,866

27,664

24,124

0

0

0

Loss from operations

-23,399

-23,288

-23,694

-23,930

-24,306

-25,710

-26,384

-30,045

-32,075

-34,419

-36,058

-34,650

-36,031

-36,460

-39,727

-39,767

-40,397

-39,302

-39,116

-43,857

-44,838

-45,043

-41,481

-35,945

-32,915

-31,773

-32,254

-33,423

-33,603

-34,606

-35,018

-33,446

-32,617

-25,866

-22,664

-20,110

0

0

0

Interest expense

323

514

738

958

1,134

1,154

1,139

1,136

1,193

1,396

1,590

1,775

1,907

1,721

1,481

1,241

998

939

1,016

1,174

1,411

1,719

2,031

2,335

2,633

2,917

3,133

2,823

2,371

1,855

0

0

0

-

-

0

0

-

-

Other income, net

477

472

392

285

238

249

282

286

371

357

276

258

167

158

144

1,877

3,761

3,565

13,711

10,306

8,692

3,760

-5,344

-2,858

-1,999

92

3,914

-5,016

-5,677

-7,490

-12,346

-1,921

-2,714

5,984

6,179

3,855

0

0

0

Net loss

-23,245

-23,330

-24,040

-24,603

-25,202

-26,615

-27,241

-30,895

-32,897

-35,458

-37,372

-36,167

-37,771

-38,023

-41,064

-39,131

-37,634

-36,676

-26,421

-34,725

-37,557

-43,002

-48,856

-41,138

-37,547

-34,598

-31,473

-41,262

-41,651

-43,951

-48,639

-36,257

-35,905

-20,141

-16,485

-16,255

0

0

0

Unrealized loss on available-for-sale securities

0

-

-

-

-

7

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain on available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-10

-20

-11

-3

6

7

-4

7

2

-9

-4

-18

-7

-13

-41

12

5

9

19

-23

-23

11

34

0

0

0

-

-

Comprehensive loss

-23,245

-23,329

-24,040

-24,602

-25,197

-26,608

-27,240

-30,887

-32,884

-35,443

-37,368

-36,177

-37,791

-38,034

-41,067

-39,125

-37,627

-36,680

-26,414

-34,723

-37,566

-43,006

-48,874

-41,145

-37,560

-34,639

-31,461

-41,257

-41,642

-43,932

-48,662

-36,280

-35,894

-20,107

0

0

0

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

72,513

-

-

-

60,246

-

-

51,698

51,630

-

-

47,398

46,953

-

-

-

46,295

45,894

-

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

72,525

-

-

-

61,895

-

-

53,271

53,268

-

-

47,398

47,286

-

-

-

46,295

47,866

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.12

-

-

-

-0.20

-

-

-0.15

-0.16

-

-

-0.37

-0.18

-

-

-

-0.18

0.04

-

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.15

-

-

-

-0.20

-

-

-0.16

-0.18

-

-

-0.37

-0.20

-

-

-

-0.18

0.04

-

-

Basic and diluted loss per common share:
Net loss

-23,245

-23,330

-24,040

-24,603

-25,202

-26,615

-27,241

-30,895

-32,897

-35,458

-37,372

-36,167

-37,771

-38,023

-41,064

-39,131

-37,634

-36,676

0

0

0

-

-48,856

-41,138

-37,547

-34,598

-31,473

-41,262

-41,651

-43,951

-48,639

-36,257

-35,905

-20,141

-16,485

-16,255

0

0

0

Shares used in computing net loss per common share

111,393

112,114

105,070

72,190

59,142

37,471

36,095

34,417

34,345

31,836

23,678

21,521

21,029

-

14,503

14,493

14,443

-

12,463

-

67,641

-

60,549

-

56,313

-

-

-

51,587

-

-

-

46,793

-

46,714

-

-

-

-

Net loss per common share

-0.05

-0.02

-0.06

-0.09

-0.10

-0.16

-0.18

-0.20

-0.21

-0.14

-0.43

-0.41

-0.47

-

-0.62

-0.72

-0.70

-

-0.56

-

-0.13

-

-0.25

-

-0.26

-

-

-

-0.23

-

-

-

-0.30

-

-0.11

-

-

-

-

Basic and diluted loss attributable to common stockholders per common share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.14

-0.44

Shares used in computing basic and diluted net loss per common share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

36,970

10,912